Bevacizumab Versus Ranibizumab in the Treatment of XXXX Due to @entity2994 : 6-Month Results of the CRAVE Study.

@entity1 @entity2994 @entity1103
BACKGROUND AND OBJECTIVE: To compare efficacy of monthly treatment with bevacizumab or ranibizumab for @entity1103 due to @entity2994 . @entity1 AND METHODS: Randomized, multicenter, comparative trial (ClinicalTrials.gov identifier: NCT01428388). @entity1 were randomized 1:1 to receive monthly treatment with bevacizumab or ranibizumab. The primary outcome was change in central foveal thickness at 6 months compared to baseline. RESULTS: The trial randomized 98 @entity1 to treatment with bevacizumab or ranibizumab. At 6 months, there were no differences in change in central foveal thickness between groups (bevacizumab: mean reduction of 212.6   m, 95% confidence interval [CI], -288.3 to -137.0; ranibizumab: mean reduction of 243.8   m, 95% CI, -309.6 to -178.0; P = .72, analysis of variance [ANOVA]). Both groups showed similar functional outcomes (bevacizumab: 0.33 logMAR gain, 95% CI, -0.47 to -0.18; ranibizumab: 0.34 logMAR gain, 95% CI, -0.45 to -0.23; P = .38, ANOVA). CONCLUSION: In the treatment of @entity2994 , bevacizumab and ranibizumab have similar effects on reducing macular thickness and improving visual acuity. [Ophthalmic Surg Lasers Imaging Retina. 2015;46:844-850.].
